Previous studies have shown that other approaches such as IFN‐A/peg‐IFN‐A,28, 29 a BCL‐2 inhibitor (venetoclax), a JAK2 inhibitor (ruxolitinib), a BTK inhibitor, a PPAR‐γ (pioglitazone),30 and a PD‐1 antibody in combination with TKI, can be applied to eliminate CML stem cells in patients with CML not achieving DMR with TKI monotherapy.31, 32. The gene discussed is BCL2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.